# Phase 4 Diabetes Mellitus, Type 2 trials: 79 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 79 trials in phase 4 for Diabetes Mellitus, Type 2 that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 Diabetes Mellitus, Type 2 trials: 79 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/diabetes-mellitus-type-2

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 79
- Recruiting or not yet: 79
- Read on: November 19, 2026

## Trials

The 25 newest of 79, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939750 | Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes | Allied Hospital Faisalabad | Phase 4 | Not yet recruiting | Type 2 Diabetes Mellitus (DM) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939750) |
| October 23, 2026 | NCT07891234 | Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | MAFLD in Prediabetes and Diabetes | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891234) |
| October 1, 2026 | NCT07852988 | Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes | Silesian Centre for Heart Diseases | Phase 4 | Recruiting | Type 2 Diabetes (T2DM) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852988) |
| September 10, 2026 | NCT07811427 | Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A... | Baim Institute for Clinical Research | Phase 4 | Not yet recruiting | Chronic Kidney Disease, Type II Diabetes | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811427) |
| September 2, 2026 | NCT07800468 | Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy | Wah Medical college , POF hospital | Phase 4 | Not yet recruiting | Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies, Type 2 Diabetes | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800468) |
| August 18, 2026 | NCT07771010 | The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2... | University Medical Centre Ljubljana | Phase 4 | Recruiting | Diabetes Type 2 | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771010) |
| August 5, 2026 | NCT07747402 | Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes | Xi'an International Medical Center Hospital | Phase 4 | Not yet recruiting | Type 2 Diabetes | 462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747402) |
| July 31, 2026 | NCT07739537 | PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses | Massachusetts General Hospital | Phase 4 | Not yet recruiting | Diabete Type 2, Pharmacogenomic Drug Interaction | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739537) |
| July 29, 2026 | NCT07733232 | Fecal Microbiota Transplantation for Type 2 Diabetes Mellitus and Hashimoto's Thyroiditis | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Autoimmune Thyroid Disease, Type 2 Diabetes Mellitus (T2DM), FMT | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733232) |
| July 22, 2026 | NCT07719894 | Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes | Seoul National University Bundang Hospital | Phase 4 | Recruiting | Type 2 Diabetes Mellitus (T2DM), Atherosclerosis | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719894) |
| July 17, 2026 | NCT07711171 | Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment | Fudan University | Phase 4 | Recruiting | Type 2 Diabetes Mellitus, Cognitive Impairment | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711171) |
| July 15, 2026 | NCT07704190 | Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease | Peking University Third Hospital | Phase 4 | Not yet recruiting | Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704190) |
| July 13, 2026 | NCT07697391 | AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | The First Affiliated Hospital of Anhui Medical University | Phase 4 | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697391) |
| June 25, 2026 | NCT07667517 | Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease | First Affiliated Hospital of Zhejiang University | Phase 4 | Not yet recruiting | Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667517) |
| May 29, 2026 | NCT07614230 | SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | Sponsor not shown (see the record) | Phase 4 | Recruiting | Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease, Atherosclerosis | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614230) |
| May 14, 2026 | NCT07588438 | Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Las Rías Medical Center | Phase 4 | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588438) |
| April 30, 2026 | NCT07558863 | Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes | The First Affiliated Hospital with Nanjing Medical University | Phase 4 | Recruiting | Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558863) |
| April 29, 2026 | NCT07555730 | AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Huazhong University of Science and Technology | Phase 4 | Not yet recruiting | Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555730) |
| April 17, 2026 | NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic... | First Affiliated Hospital of Wannan Medical College | Phase 4 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537088) |
| March 27, 2026 | NCT07494084 | Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance | Washington State University | Phase 4 | Recruiting | Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494084) |
| March 20, 2026 | NCT07485062 | Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes | Western University, Canada | Phase 4 | Not yet recruiting | Type 2 Diabetes, Cognitive Decline in Older Adults | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485062) |
| March 2, 2026 | NCT07442006 | Glycemic Variability of Combination Therapies in T2DM | JW Pharmaceutical | Phase 4 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07442006) |
| February 27, 2026 | NCT07436182 | Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin... | Mansoura University | Phase 4 | Not yet recruiting | Mitochondria, Metformin | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436182) |
| February 11, 2026 | NCT07401992 | Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Hospital Universitario Dr. Jose E. Gonzalez | Phase 4 | Recruiting | Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2 | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401992) |
| January 26, 2026 | NCT07365358 | Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | Chong Kun Dang Pharmaceutical | Phase 4 | Not yet recruiting | Diabete Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365358) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Seoul National University Bundang Hospital | 7 |
| University Medical Centre Ljubljana | 2 |
| Stanford University | 2 |
| Yonsei University | 2 |
| Massachusetts General Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| Federico II University | 1 |
| First Affiliated Hospital of Wannan Medical College | 1 |
| The First Affiliated Hospital of Anhui Medical University | 1 |
| University of Michigan | 1 |
| General Hospital of Shenyang Military Region | 1 |
| Second Affiliated Hospital of Nanchang University | 1 |
| University Medical Center, Kazakhstan | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| Las Rías Medical Center | 1 |
| [JW Pharmaceutical](https://specstream.ai/data/clinical-trials/company/jw-pharmaceutical) | 1 |
| [Chong Kun Dang Pharmaceutical](https://specstream.ai/data/clinical-trials/company/chong-kun-dang-pharmaceutical) | 1 |
| Universitas Indonesia | 1 |
| Huazhong University of Science and Technology | 1 |
| Getz Pharma | 1 |
| Amsterdam UMC, location VUmc | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Peking University Third Hospital | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 21 |
| United States | 13 |
| South Korea | 13 |
| Denmark | 3 |
| Canada | 3 |
| Italy | 2 |
| Egypt | 2 |
| Pakistan | 2 |
| Netherlands | 2 |
| Slovenia | 2 |
| Kazakhstan | 1 |
| Mexico | 1 |
| Paraguay | 1 |
| Indonesia | 1 |
| Afghanistan | 1 |
| Kenya | 1 |
| Nigeria | 1 |
| Sri Lanka | 1 |
| Germany | 1 |
| Poland | 1 |
| Taiwan | 1 |
| Hong Kong | 1 |
| Austria | 1 |
| New Zealand | 1 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pest control companies in the United States](https://specstream.ai/data/businesses/pest-control-companies/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Maternity centers in the United States](https://specstream.ai/data/businesses/maternity-centers/united-states)
- [Anesthesiology practices in the United States](https://specstream.ai/data/businesses/anesthesiology-practices/united-states)
- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Tires manufacturers in the United States](https://specstream.ai/data/businesses/tires-manufacturers/united-states)
